Normunity

Normunity is a clinical-stage biotechnology company developing novel anti-cancer therapies that work at the interface of the immune system and the tumor. In collaboration with the Lieping Chen lab at the Yale School of Medicine, Normunity has identified a novel class of "Immuno-smart targets" — tumor-specific, cell-surface proteins co-opted by cancer cells to drive local immune suppression — and is building a pipeline of biologic medicines including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Its lead program, NRM-823, is a T cell engager that has entered clinical trials. Normunity is backed by Canaan Partners. This is a corporate/scientific company with no public API, developer portal, or programmatic surface.

Normunity is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immuno-Oncology, Oncology, and Cancer.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiotechnologyImmuno-OncologyOncologyCancerTherapeuticsImmunologyAntibodiesClinical TrialsPharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/normunity: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

LinkedIn

Other 1

Properties that don't map to a standard resource type

Source (apis.yml)

aid: normunity
name: Normunity
description: Normunity is a clinical-stage biotechnology company developing novel anti-cancer therapies that work at the interface
  of the immune system and the tumor. In collaboration with the Lieping Chen lab at the Yale School of Medicine, Normunity
  has identified a novel class of "Immuno-smart targets" — tumor-specific, cell-surface proteins co-opted by cancer cells
  to drive local immune suppression — and is building a pipeline of biologic medicines including therapeutic antibodies, bispecific
  antibodies, and payload-carrying biologics. Its lead program, NRM-823, is a T cell engager that has entered clinical trials.
  Normunity is backed by Canaan Partners. This is a corporate/scientific company with no public API, developer portal, or
  programmatic surface.
url: https://raw.githubusercontent.com/api-evangelist/normunity/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Oncology
- Cancer
- Therapeutics
- Immunology
- Antibodies
- Clinical Trials
- Pharmaceuticals
image: https://normunity.com/wp-content/uploads/2022/10/normunity-logo.png
apis: []
common:
- type: Website
  url: https://normunity.com/
- type: X
  url: https://x.com/normunity
- type: LinkedIn
  url: https://www.linkedin.com/company/normunity
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1
  note: Clinical-stage immuno-oncology biotech; no public API, developer portal, or programmatic surface. Identity hygiene
    enriched; domain probed.